版本:
中国

BRIEF-Eiger completes enrollments for phase 2 in hypoglycemia study

June 6 Eiger Biopharmaceuticals Inc

* Eiger completes enrollment in phase 2 multiple-ascending dose study of exendin 9-39 in post-bariatric hypoglycemia patients Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐